Taken together, these findings indicate that ADT-induced upregulation of TDO2 prevented ADT-induced death of dormant prostate cancer cells and preserved drug tolerance, whereas TDO2 or AhR inhibition promoted ADT-induced death of dormant cells. Here, AHR is linked to prostate carcinoma.